ReviewFrontiers in medicine2026
Global seroprevalence of neutralizing and total antibodies against AAV vectors and their impact on the clinical gene therapy landscape: a scoping review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-existing neutralizing antibodies (NAbs) and total antibodies (TAbs) against adeno-associated virus (AAV) vectors represent a major barrier to the clinical translation of AAV-based gene therapies. A comprehensive characterization of their global prevalence, determinants, and clinical implications is currently lacking. We conducted a scoping review of 50 studies published between 1968 and 2026, systematically identifying seroprevalence data across AAV serotypes, populations, and geographic regions. We complemented this evidence with a structured analysis of 222 interventional AAV gene therapy trials registered in ClinicalTrials.gov, examining serotype distribution, therapeutic areas, enrollment, and immunogenicity outcomes. We found AAV2, AAV8, and AAV5 were the most extensively studied serotypes. Seroprevalence increased consistently with age and varied by geographic region, although the limited number of studies from Africa and Latin America precludes robust regional conclusions. The median trial enrollment was 14 participants, and NAb exclusion criteria markedly reduce already limited eligible populations. Long-term follow-up data indicate that declining transgene expression is frequently associated with capsid-directed cellular immunity. Standardized serological assays, region-specific seroprevalence data, and immunomodulatory strategies are essential to maximize patient eligibility and therapeutic durability in AAV gene therapy programs globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.